A Material Transfer Agreement format usually follows one of two standardized templates backed by the National Institutes of Health: the Uniform Biological Material Transfer Agreement (UBMTA) for transfers between academic and nonprofit institutions, or the NIH Simple Letter Agreement (SLA) for straightforward one-off transfers. Both formats cover the same core elements — identification of the parties, a precise description of the material, ownership and intellectual property terms, use restrictions, publication review, confidentiality, and liability. Custom-drafted agreements are reserved for transfers involving for-profit entities, unusual materials, or terms that depart from the standard templates.
What a Material Transfer Agreement Contains
Every MTA, templated or custom, is built around the same categories of information. Getting any of them wrong can invalidate the agreement or create ambiguity about who owes what to whom.
The Parties and the Researchers
The opening section identifies the full legal names of the providing and receiving institutions, their official contact information, and the lead researchers (often called Principal Investigators, or PIs) on each side with their departmental affiliations. Errors in this section are not administrative trivia. They can invalidate the agreement or make it unclear which institution bears the obligations.
The Material Description
This is the single most important field. The description has to be specific enough to distinguish the substance from anything else in either party’s inventory. Not “cell line” but the exact cell line designation, passage number, genetic modifications, or chemical formula. Vague descriptions invite disputes later about what was actually covered. If the transfer includes associated data, software, or protocols, those should be listed separately, since they may require a Data Use Agreement rather than, or in addition to, the MTA.
Ownership and Intellectual Property
The provider keeps ownership of the original material. Under the UBMTA, the provider also retains ownership of any provider material that gets physically incorporated into something the recipient creates (called “modifications”). The recipient owns the modifications themselves, minus the provider’s material embedded in them, and owns any new substances created through use of the material that don’t physically contain it.
This split is where most negotiation friction occurs. Providers sometimes try to claim ownership over anything the recipient develops using the material, including inventions that don’t incorporate the material at all. NIH policy treats definitions of “materials” that sweep in all derivatives, improvements, or anything that “could not have been made” without the provided material as unacceptable for NIH-funded research.1National Institutes of Health. Research Tools Policy
Use Restrictions
Standard MTAs limit the recipient to noncommercial research and teaching. The UBMTA defines “commercial purposes” broadly: not just selling the material, but using it for contract research, screening compound libraries, manufacturing products, or transferring the material or modifications to a for-profit entity.2National Institutes of Health. Uniform Biological Material Transfer Agreement Industrially sponsored academic research gets a carve-out, but the line can blur quickly.
Commercial use requires a separate license. The UBMTA requires the recipient to negotiate in good faith with the provider for commercial terms before any such use, but the provider has no obligation to grant a license.2National Institutes of Health. Uniform Biological Material Transfer Agreement Industry-adjacent researchers sometimes discover late in a project that their MTA blocks the path to commercialization.
Reach-Through Rights
Reach-through provisions give the provider a financial stake in whatever the recipient develops using the material: royalties on future products, exclusive licenses to inventions, or options on commercial rights. NIH policy on this is explicit. For NIH-funded materials transferred from nonprofit entities, agreements should not include commercialization option rights, royalty reach-through, or product reach-through rights.1National Institutes of Health. Research Tools Policy The Bayh-Dole Act reinforces this by allowing nonprofit organizations and small businesses to retain title to inventions made with federal funding, meaning an MTA provider cannot require you to assign title to inventions back to them as a condition of receiving federally funded materials.3Office of the Law Revision Counsel. United States Code Title 35 Section 202
Publication Review
Most MTAs include a pre-publication review window, typically 30 to 60 days, during which the provider can review manuscripts that describe research using their material. The purpose is to identify any inadvertent disclosure of proprietary information or patentable subject matter, not to veto publication. An MTA that gives the provider authority to block publication is inconsistent with academic norms and should be treated as a red flag.
Confidentiality and Liability
Confidentiality clauses protect proprietary information shared alongside the physical material, such as protocols, formulas, and unpublished data. These obligations usually survive the agreement’s termination.
Liability provisions are standard but important. The provider delivers material “as is” with no guarantee it will work for any particular experiment. The recipient typically agrees to indemnify the provider against claims arising from the recipient’s use of the material. These clauses exist because research materials are inherently unpredictable, and providers would stop sharing if every failed experiment became a potential lawsuit.
Termination and Material Disposition
Standard agreements require the recipient to return or destroy any remaining material (and derivatives, depending on how the agreement defines them) when the contract expires or is terminated, and usually to certify that in writing. Confidentiality and IP obligations survive termination. Using the material for a commercial purpose without a license, or sharing it with an unauthorized third party, typically gives the provider the right to terminate immediately and demand return of all materials.
The Two Standard Formats
Most academic transfers don’t need a custom-drafted contract. Two NIH-backed templates handle the majority of nonprofit-to-nonprofit transfers, and the choice between them depends on how often the two institutions expect to exchange material.
The Uniform Biological Material Transfer Agreement
The UBMTA is the most widely used template for biological material transfers between academic institutions. NIH coordinated its development with university and industry representatives, and the Association of University Technology Managers (AUTM) serves as the repository for signed master agreements.4National Institutes of Health. Uniform Biological Material Transfer Agreement Request for Comments
The format has two tiers. A Master Agreement establishes the overarching legal relationship between two institutions. An Implementing Letter is then executed for each individual transfer, identifying the specific material, the researchers involved, and the permitted use. Once both institutions have signed the Master Agreement, every subsequent transfer between them requires only an Implementing Letter, which two scientists can fill out in an afternoon. Institutions that haven’t signed the Master Agreement can either sign it or use AUTM’s standalone templates that incorporate the same terms.5AUTM. Uniform Biological Material Transfer Agreement
The NIH Simple Letter Agreement
The Simple Letter Agreement is a standalone, one-page MTA developed by NIH for straightforward transfers. It’s the preferred model for NIH’s intramural program when transferring non-human, non-animal, non-hazardous research materials to nonprofits. NIH encourages recipients of its funding to adopt the SLA as their institution’s default MTA because each round of negotiation delays the moment a research tool reaches the lab.6National Institutes of Health. NIH Simple Letter Agreement Where the UBMTA requires a pre-existing Master Agreement between institutions, the SLA works as a standalone document with no institutional relationship needed beforehand.
When Neither Template Fits
Custom agreements become necessary when the transfer involves a for-profit entity, when the material carries unusual restrictions (export-controlled technology, human tissue with consent limitations), or when the parties want terms that differ from the UBMTA’s default positions on IP and commercial use. These bespoke agreements take substantially longer to negotiate and should involve your Technology Transfer Office (TTO) from the start.
How the Agreement Gets Executed
Only authorized institutional signatories, typically officials in the sponsored programs office, legal department, or TTO, have the legal power to bind an institution to an MTA. A Principal Investigator’s signature doesn’t execute the agreement. PIs often sign a separate acknowledgment confirming they’ve read and understood the terms, but that signature carries no binding authority on its own.
Both parties must sign the same version of the document. When agreements go through multiple revision cycles over email, version mismatches happen more often than you’d expect, which is why most institutions now use electronic signature platforms. Once all required signatures are in place and the recipient holds a fully executed copy, the provider can legally ship the material. Not before.
Before anyone touches a template, most institutions route MTA requests through a TTO or Office of Sponsored Programs. The TTO typically provides an internal request form that walks the researcher through the required fields: material description, intended use, funding source, and whether commercial applications are anticipated. Completing these forms accurately up front prevents the most common delay, which is the TTO sending the form back for clarification.
How Long It Takes
Plan for one to three months from initial request to executed agreement. Transfers between academic or nonprofit institutions move faster. AUTM survey data shows that roughly 70 percent are completed within a month, and over 90 percent within three months. Agreements involving for-profit entities take longer: only about 45 percent finish within a month, though nearly 80 percent are done by three months.7AUTM. Material Transfer Agreements for Technology The biggest time sinks are disputes over IP ownership, reach-through provisions, and publication restrictions. Using a standardized template like the UBMTA or SLA eliminates most of those arguments before they start.
What the MTA Itself Does Not Cover
A signed MTA governs the legal relationship between the parties, not the physical act of shipping. Depending on what’s being transferred, federal regulations may separately require CDC or USDA APHIS permits, Department of Transportation hazardous materials packaging, select agent authorizations, or export control review under ITAR, EAR, or OFAC sanctions screening. These regimes operate independently of the agreement’s format and have their own timelines and paperwork. Your institution’s biosafety office and export control office should be looped in early on any transfer that involves infectious agents, select agents, or international shipment, because the MTA alone will not satisfy them.